WallStSmart

Harrow Health Inc (HROW)vsViatris Inc (VTRS)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 4756% more annual revenue ($14.73B vs $303.25M). VTRS leads profitability with a -4.1% profit margin vs -9.4%. VTRS earns a higher WallStSmart Score of 40/100 (D).

HROW

Hold

40

out of 100

Grade: F

Growth: 10.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: 0.76

VTRS

Hold

40

out of 100

Grade: D

Growth: 2.0Profit: 3.5Value: 3.0Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HROW.

VTRSSignificantly Overvalued (-81.4%)

Margin of Safety

-81.4%

Fair Value

$8.89

Current Price

$20.67

$11.78 premium

UndervaluedFair: $8.89Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HROW2 strengths · Avg: 10.0/10
Revenue GrowthGrowth
38.6%10/10

Revenue surging 38.6% year-over-year

EPS GrowthGrowth
810.0%10/10

Earnings expanding 810.0% YoY

VTRS1 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

Areas to Watch

HROW4 concerns · Avg: 2.3/10
Market CapQuality
$1.10B3/10

Smaller company, higher risk/reward

Price/BookValuation
38.1x2/10

Trading at 38.1x book value

Return on EquityProfitability
-35.4%2/10

ROE of -35.4% — below average capital efficiency

Free Cash FlowQuality
$-9.95M2/10

Negative free cash flow — burning cash

VTRS4 concerns · Avg: 2.0/10
PEG RatioValuation
3.732/10

Expensive relative to growth rate

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

Revenue GrowthGrowth
-0.3%2/10

Revenue declined 0.3%

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Comparative Analysis Report

WallStSmart Research

Bull Case : HROW

The strongest argument for HROW centers on Revenue Growth, EPS Growth. Revenue growth of 38.6% demonstrates continued momentum.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book.

Bear Case : HROW

The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 19.79 is elevated, increasing financial risk.

Bear Case : VTRS

The primary concerns for VTRS are PEG Ratio, Return on Equity, Revenue Growth.

Key Dynamics to Monitor

HROW profiles as a hypergrowth stock while VTRS is a turnaround play — different risk/reward profiles.

VTRS carries more volatility with a beta of 0.87 — expect wider price swings.

HROW is growing revenue faster at 38.6% — sustainability is the question.

VTRS generates stronger free cash flow (329M), providing more financial flexibility.

Bottom Line

HROW scores higher overall (40/100 vs 40/100) and 38.6% revenue growth. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Harrow Health Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?